| 10/22/2015 | CV | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
| 10/20/2009 | CV | Sepracor plans to hold change-of-control offer for convertibles
|
| 9/3/2009 | CV | Market Commentary: Sepracor adds on takeout news; Terex, Newmont rise with shares; NetApp weakens on tepid demand
|
| 8/5/2009 | CV | Sepracor buys $48.2 million of its zero-coupon notes for $43.8 million
|
| 3/17/2009 | CV | Sepracor holders tender $143.45 million 0% convertibles due 2024
|
| 2/17/2009 | CV | Sepracor begins tender offer for 0% convertibles due 2024
|
| 11/19/2008 | CV | Market Commentary: Ford falls as rescue hopes dim; Chesapeake, Transocean, Prudential see strength; Sepracor trading picks up
|
| 8/11/2008 | CV | Sepracor buys back $21.3 million of its 0% convertibles due 2024
|
| 7/3/2007 | CV | June convertibles returns down after credit spreads rise, stock market falls, Citi says
|
| 6/29/2006 | CV | Market Commentary: Red Hat rises dollar-neutral, falls outright; new Vector bid higher; CNET, Intel gain; Nexans prices deal
|
| 6/5/2006 | CV | Market Commentary: SanDisk gains outright on stock upgrade; Sepracor falls on probe; Interpublic plans unique deal
|
| 5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
| 5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
| 2/13/2006 | BTCV | S&P upgrades Sepracor
|
| 1/31/2006 | CV | Market Commentary: Earnings send Sepracor higher, but UnumProvident, Goodyear lower; Huntsman adds on takeout talk
|
| 11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
| 10/25/2005 | CV | Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
|
| 9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
| 7/18/2005 | CV | Market Commentary: Convertibles market pauses ahead of earnings; Genzyme falls amid mixed biotechs, Lucent, financials ease
|
| 4/25/2005 | CV | Market Commentary: Merger news pushes DoubleClick, Valero higher; Calpine continues slide; Sepracor 0s up, 5s decline
|
| 2/18/2005 | CV | Market Commentary: Lions Gate, BlackRock, Sybase weak; Sepracor's older convertibles bleed; Fannie credit holding up
|
| 2/17/2005 | CV | Market Commentary: BlackRock lifted; Lions Gate rolls out; Sepracor arbs hurt; REITs hit; Royal Caribbean call risk allayed
|
| 2/9/2005 | CV | Market Commentary: Protein Design Labs sweetened, sinks; Huntsman hotly pursued; Allergan, Sepracor off, Saks up
|
| 10/18/2004 | CV | Sepracor extends greenshoe exercise deadline
|
| 10/15/2004 | CV | Top volatility plays: BankUnited, Schlumberger, Teva, HCC Insurance, Quanex, Merrill says
|
| 9/20/2004 | CV | Market Commentary: Beazer, Lennar drop; Novell overtaking Red Hat as Linux pick; Delta, airlines ease back
|
| 9/17/2004 | CV | Market Commentary: Sepracor issue straddles par; Vitesse goes to 103; EDS firm despite warning; biotechs rally
|
| 9/17/2004 | CV | New Issue: Sepracor sells $500 million convertibles at 0%, up 30%
|
| 9/17/2004 | CVDD | S&P rates Sepracor convertibles CCC+
|
| 9/16/2004 | CV | Market Commentary: Sepracor, Vitesse deals emerge; Delta converts steady; Nortel, Lucent tumble; Providian better
|
| 9/16/2004 | CV | Sepracor $500 million overnight convertible talked to yield 0%, up 26%-34%
|
| 9/10/2004 | CV | Sepracor exchanges further $25 million convertibles for stock and cash
|
| 9/7/2004 | CVDD | S&P: Sepracor unaffected
|
| 9/3/2004 | CV | Sepracor exchanges $504 million 0% convertibles for stock, cash
|
| 7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
| 6/7/2004 | CV | Market Commentary: Mandalay event sparks furor on concern about no cash takeover protection; 20-30 names suffer
|
| 3/26/2004 | CVDD | S&P: Sepracor unaffected
|
| 3/2/2004 | CV | Market Commentary: Avnet, Bell Micro gain; Amdocs slips; in gray, PSS bid plus 1 point, First Horizon at plus 0.25 point
|
| 3/1/2004 | CV | Market Commentary: Sepracor news wakes a raging bidding war in converts; 4 new deals emerge, including Amdocs
|
| 3/1/2004 | CVDD | S&P: Sepracor outlook positive
|
| 1/12/2004 | CV | Sepracor greenshoe exercised, raising convertibles to $750 million
|
| 1/8/2004 | CV | Sepracor extends greenshoe exercise deadline
|
| 1/7/2004 | CV | Market Commentary: Coeur d'Alene bid up 1 point in gray market; Red Hat hits 103.25 bid; Duke rebounds
|
| 12/15/2003 | CV | Sepracor calls 5.75% convertibles
|
| 12/10/2003 | CV | Market Commentary: Magnum, Scottish Re, CenterPoint emerge; Emulex, Akamai decline; Wyeth bid 0.5 over par in gray
|
| 12/10/2003 | CVDD | S&P rates new Sepracor convertible CCC+
|
| 12/9/2003 | CV | Market Commentary: Another $2.575 billion of deals; Akamai, Emulex both reoffered at 98
|
| 12/9/2003 | CV | New Issue: Sepracor $200 million convert at 0%, up 24%, $400 million convert at 0%, up 16%
|
| 12/9/2003 | CVDD | S&P rates new Sepracor convertibles CCC
|
| 12/8/2003 | CV | Sepracor to sell $200 million convertible at 0%, up 24-32%; $400 million convert at 0%, up 16-24%
|
| 12/8/2003 | CV | Market Commentary: Issuers unwrap $1.73 billion of new paper and more set to come this week, this month
|
| 12/3/2003 | CV | S&P: Sepracor ratings unaffected by drug news
|
| 6/3/2003 | CV | Market Commentary: Mirant 5.75s fall 12-15 points on bankruptcy buzz; six new deals afloat in primary
|
| 6/3/2003 | CV | Valassis buys back $185.3 million 0% convertibles with proceeds of new deal
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
| 9/24/2002 | CV | Sepracor buys back $131.1 million 7% convertibles
|
| 4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
| 4/5/2002 | CV | Salomon: Shrinking premiums, rising delta signal times to shift positions
|
| 3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
| 3/19/2002 | CV | Salomon analyst: Buy Sepracor 7% convertibles on weakness
|
| 3/15/2002 | CV | Market Commentary: Convertibles edge up, quiet after busy week of new deals
|
| 3/8/2002 | CV | Market Commentary: Convertibles gain on Nasdaq strength; Alpharma drops
|
| 3/7/2002 | CV | Market Commentary: Convertibles stall with stocks; oils, financials gain
|
| 3/7/2002 | CV | Sepracor explodes on surprise setback from FDA on new drug
|
| 2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|
| 1/3/2002 | CV | Moody's puts Xerox on review for downgrade
|
| 12/24/2001 | CV | Market Commentary: Convertibles mixed, flat on light volume in holiday-shortened session
|
| 12/21/2001 | CV | Sepracor says greenshoe exercised, raising convertibles to $500 million
|
| 11/27/2001 | CV | Market Commentary: Convertible market seen flat on heavy trading from high volatility
|
| 11/8/2001 | CV | Market Commentary: Convertible market ends flat, new deals getting richer
|
| 11/8/2001 | CV | New Issue: Sepracor sells $400 million convertibles at 5.75% yield, up 24.7%
|
| 11/7/2001 | CV | Market Commentary: Convertible market gains with spate of new deals
|
